<DOC>
	<DOCNO>NCT00941863</DOCNO>
	<brief_summary>The primary objective study define safety profile maximum tolerate dose ( MTD ) sorafenib tablet combination carboplatin paclitaxel chemotherapy patient advance , refractory solid tumor . The secondary objective evaluation pharmacokinetics ( PK ) tumor response patient treat sorafenib combination paclitaxel carboplatin .</brief_summary>
	<brief_title>Study Determine Safety , Maximum Tolerated Dose , Pharmacokinetics Sorafenib ( BAY43-9006 )</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm solid tumor Evaluable disease Eastern Cooperative Oncology Group ( ECOG ) 0 1 Life expectancy minimum 12 week Congestive heart failure Serious arrhythmia Coronary artery disease ( CAD ) ischemia HIV ( human immunodeficiency virus ) Hepatitis B C Serious active infection Metastatic brain meningeal tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Carboplatin paclitaxel chemotherapy combination</keyword>
</DOC>